Public Profile

Centrient Pharmaceuticals

Centrient Pharmaceuticals, headquartered in the Netherlands, is a leading player in the global pharmaceutical industry, specialising in the development and manufacturing of essential antibiotics and anti-infectives. Founded in 2017, the company has quickly established itself as a key provider of high-quality, sustainable pharmaceutical solutions, with a strong operational presence across Europe, Asia, and North America. Centrient's core offerings include a diverse range of generic and branded antibiotics, as well as innovative formulations that address critical healthcare needs. The company is recognised for its commitment to sustainability and responsible manufacturing practices, setting it apart in a competitive market. With a focus on quality and patient safety, Centrient Pharmaceuticals continues to achieve significant milestones, reinforcing its position as a trusted partner in the healthcare sector.

DitchCarbon Score

How does Centrient Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

37

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Centrient Pharmaceuticals's score of 37 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.

76%

Let us know if this data was useful to you

Centrient Pharmaceuticals's reported carbon emissions

In 2023, Centrient Pharmaceuticals reported total carbon emissions of approximately 142,740,000 kg CO2e for Scope 1, 141,369,000 kg CO2e for Scope 2, and 448,232,000 kg CO2e for Scope 3 emissions. This represents a total of about 284,109,000 kg CO2e for Scope 1 and 2 combined. The company has set ambitious reduction targets, aiming for a 35% reduction in carbon emission intensity by 2025 and a 50% reduction by 2030. Furthermore, Centrient has committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by 2031, using 2022 as the base year. Additionally, they aim to cut Scope 3 emissions from purchased goods and services and fuel and energy-related activities by 27.5% within the same timeframe. These targets align with industry standards and reflect Centrient's commitment to addressing climate change and reducing its carbon footprint.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

202120222023
Scope 1
87,494,000
000,000,000
000,000,000
Scope 2
202,885,000
000,000,000
000,000,000
Scope 3
-
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Centrient Pharmaceuticals's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Centrient Pharmaceuticals is in NL, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Centrient Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers